Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2020 September;62(3) > Panminerva Medica 2020 September;62(3):125-30

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Panminerva Medica 2020 September;62(3):125-30

DOI: 10.23736/S0031-0808.19.03678-4

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Sensitivity of hepatitis C virus rapid tests in detecting antibodies in general population

Paola CHIONNE 1, Elisabetta MADONNA 1, Umbertina VILLANO 1, Elena TRITARELLI 1, Giulio PISANI 2, Angela COSTANTINO 1, Michele EQUESTRE 3, Cinzia MARCANTONIO 1, Roberto BRUNI 1, Anna R. CICCAGLIONE 1

1 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; 2 Center for Immunobiologicals Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy; 3 Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy



BACKGROUND: Evaluation of clinical performance of the anti-hepatitis C virus (HCV) rapid tests were carried out mostly in chronic hepatitis C patients and in individuals at high risk of HCV infection.
METHODS: The aim of this study was to evaluate the performance of OraQuick and Wantai rapid tests on archived serum samples from 1408 individuals (mean age 46, range 18-90; 65% female) recruited with a systematic sampling procedure during a general population survey.
RESULTS: The analysis of samples by Ortho HCV 3.0 ELISA and Cobas Taqman HCV RNA assays resulted in 69 anti-HCV antibody positive sera, including 42 HCV RNA positive (group 1) and 27 HCV RNA negative (group 2) samples. The performance of rapid tests was evaluated on the 69 anti-HCV positive (group 1+2) and 206 (OraQuick) and 198 (Wantai) anti-HCV negative sera, randomly selected from the 1339 anti-HCV negative samples. The OraQuick and Wantai rapid assays showed a sensitivity in group 1 of 92.9% and 90.5%, respectively. The sensitivity in group 2 was 40.7% and 51.9%, respectively. The anti-HCV antibodies signal/cutoff mean value was the only parameter that statistically differed between group 1 and group 2 individuals (P<0.0001). Further, 3 (OraQuick) and 4 samples (Wantai) from group 1, with very low HCV RNA level (<25 UI/mL), were misdiagnosed by rapid assays as false negative.
CONCLUSIONS: The proportion of infections with low level of viremia and the risk associated with rapid assay failure remained to be carefully estimated in general population.


KEY WORDS: Hepacivirus; Antibodies; Clinical laboratory techniques

inizio pagina